
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
How much do you know about the impact of opioids on the endocrine and immune systems? Take our 9-question quiz to find out.






